

# Clinical trials of alogliptin

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>alogliptin vs</b>			
<a href="#">Bosi , 2011</a> [NCT00432276] n=NA	-	-	
<a href="#">DeFronzo , 2008</a> [NCT00286455] n=NA	-	-	
<a href="#">Kaku , 2011</a> n=NA follow-up:	-	-	Japan
<a href="#">Pratley , 2009</a> [NCT00286468] n=NA follow-up:	-	-	
<a href="#">Pratley , 2009</a> [NCT00286494] n=NA follow-up:	-	-	
<a href="#">Rosenstock , 2009</a> [NCT00286429] n=NA follow-up:	-	-	
<a href="#">Rosenstock , 2010</a> [NCT00395512] n=NA follow-up:	-	-	
<a href="#">Seino , 2011</a> [NCT01263509] n=NA follow-up:	-	-	

continued...

Trial	Treatments	Patients	Trials design and methods
Seino , 2011 n=NA follow-up:	-	-	Japan
<b>alogliptin vs placebo</b>			
EXAMINE , 2013 [NCT00968708] n=2701/2679 follow-up: 1.5 years (median)	alogliptin versus placebo	patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days	Parallel groups double-blind
EXAMINE , 2011 [NCT00968708] n=NA follow-up:	-	-	
<b>alogliptin vs placebo (add on MET)</b>			
Nauck , 2009 [NCT00286442] n=210/104 follow-up: 26 weeks	alogliptin 12.5 and 25 mg once daily versus placebo	patients whose HbA(1c) levels were inadequately controlled on metformin alone	Parallel groups double-blind

2

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at <http://www.trialresultscenter.org/go-Q692>

## References

Bosi , 2011:

Bosi E, Ellis GC, Wilson CA, Fleck PR Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. *Diabetes Obes Metab* 2011;13:1088-96 [21733058] [10.1111/j.1463-1326.2011.01463.x](#)

**DeFronzo , 2008:**

DeFronzo RA, Fleck PR, Wilson CA, Mekki Q Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. *Diabetes Care* 2008;31:2315-7 [18809631] [10.2337/dc08-1035](#)

**Kaku, 2011:**

Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. *Diabetes Obes Metab* 2011;13:1028-35 [21682833] [10.1111/j.1463-1326.2011.01460.x](#)

**Pratley, 2009:**

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. *Diabetes Obes Metab* 2009;11:167-76 [19125778] [10.1111/j.1463-1326.2008.01016.x](#)

**Pratley, 2009:**

Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Curr Med Res Opin* 2009;25:2361-71 [19650752] [10.1185/03007990903156111](#)

**Rosenstock, 2009:**

Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. *Diabetes Obes Metab* 2009;11:1145-52 [19758359] [10.1111/j.1463-1326.2009.01124.x](#)

**Rosenstock, 2010:**

Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. *Diabetes Care* 2010;33:2406-8 [20724648] [10.2337/dc10-0159](#)

**Seino, 2011:**

Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. *Curr Med Res Opin* 2011;27 Suppl 3:21-9 [22106975] [10.1185/03007995.2011.614936](#)

**Seino, 2011:**

Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. *Curr Med Res Opin* 2011;27:1781-92 [21806314] [10.1185/03007995.2011.599371](#)

**EXAMINE, 2013:**

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med* 2013;369:1327-35 [23992602]

Kay S, Strickson A, Puelles J, Selby R, Benson E, Tolley K Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. *Diabetes Ther* 2017;; [28275958]

**EXAMINE, 2011:**

White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F EXamination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. *Am Heart J* 2011;162:620-626.e1 [21982652]

[10.1016/j.ahj.2011.08.004](#)

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 2013 Sep 2; [23992602] [10.1056/NEJMoa1305889](#)

**Nauck, 2009:**

Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55 [19125992] [10.1111/j.1742-1241.2008.01933.x](#)

Entry terms: SYR 322, SYR322, SYR-322,